2023
Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma
Huffman B, Mallick A, Horick N, Wang-Gillam A, Hosein P, Morse M, Beg M, Murphy J, Mavroukakis S, Zaki A, Schlechter B, Sanoff H, Manz C, Wolpin B, Arlen P, Lacy J, Cleary J. Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma. JAMA Network Open 2023, 6: e2249720. PMID: 36602796, PMCID: PMC9856813, DOI: 10.1001/jamanetworkopen.2022.49720.Peer-Reviewed Original ResearchConceptsAdvanced pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinomaObjective response rateProgression-free survivalSecond-line treatmentNab-paclitaxelOverall survivalClinical trialsDuctal adenocarcinomaRandomized phase II clinical trialMedian progression-free survivalGemcitabine/nab-paclitaxelCox proportional hazards analysisEnd pointPhase II clinical trialChemotherapy dose reductionsFirst-line FOLFIRINOXSecond-line gemcitabineMedian overall survivalPrimary end pointSecondary end pointsProportional hazards analysisSurvival of patientsLow performance statusPretreatment clinical variables
1996
Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases.
Salloum E, Cooper D, Howe G, Lacy J, Tallini G, Crouch J, Schultz M, Murren J. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. Journal Of Clinical Oncology 1996, 14: 1943-9. PMID: 8656264, DOI: 10.1200/jco.1996.14.6.1943.Peer-Reviewed Original ResearchConceptsEpstein-Barr virusMTX withdrawalLymphoproliferative disordersComplete remissionPolymerase chain reactionRheumatic diseasesPartial responseAbsence of EBVNegative Epstein-Barr virusEBV RNA transcriptsSpontaneous complete remissionLow-grade lymphomaCNS involvementExtranodal diseaseImmunosuppressive therapyMethotrexate therapyMTX therapyInitial managementAggressive lymphomaClinicopathologic featuresHodgkin's diseasePathologic findingsRheumatoid arthritisSitu hybridization studiesSpontaneous regression
1994
Epstein-Barr viral nuclear antigen 1 antisense oligodeoxynucleotide inhibits proliferation of Epstein-Barr virus-immortalized B cells.
Roth G, Curiel T, Lacy J. Epstein-Barr viral nuclear antigen 1 antisense oligodeoxynucleotide inhibits proliferation of Epstein-Barr virus-immortalized B cells. Blood 1994, 84: 582-7. PMID: 8025284, DOI: 10.1182/blood.v84.2.582.bloodjournal842582.Peer-Reviewed Original ResearchConceptsEBNA-1EBNA-1 proteinAntisense oligodeoxynucleotidesEpstein-Barr virus-immortalized B cellsEpstein-Barr virus nuclear antigen 1EBV-negative cellsLatent viral proteinsNuclear antigen 1Potential therapeutic implicationsLymphoblastoid cellsEpisomal viral genomesUnmodified antisense oligodeoxynucleotidesNeoplastic diseaseTherapeutic implicationsB cellsInhibited proliferationEBVEffect of antisenseAntigen 1Antiproliferative effectsProtein expressionUntreated cellsImmortalized cellsViral proteinsProliferation
1985
Effects of diacetyl diamines on in vitro activation and proliferation of human B lymphocytes.
Lacy J, Summers W, Canellakis Z. Effects of diacetyl diamines on in vitro activation and proliferation of human B lymphocytes. The Journal Of Immunology 1985, 135: 3772-6. PMID: 3877754, DOI: 10.4049/jimmunol.135.6.3772.Peer-Reviewed Original ResearchConceptsB cell activationHuman B lymphocytesB cellsHuman B cellsB lymphocytesCell activationGrowth factor-stimulated proliferationProliferation of PHAHuman B cell activationNormal B cellsHuman T cellsT cellsProliferative responseCowan IAntiproliferative effectsSpecific abrogationInhibitory effectLymphocytesActivationProliferationHexamethylenebisacetamideCellsDerivatives of polyaminesCulture mediumDose